Tissue Regenix Group PLC New sports medicine product launch (3331L)
05 Septembre 2023 - 8:01AM
UK Regulatory
TIDMTRX
RNS Number : 3331L
Tissue Regenix Group PLC
05 September 2023
Tissue Regenix Group plc
('Tissue Regenix', the 'Group' or the 'Company')
New sports medicine product launch
Tissue Regenix Group plc (AIM: TRX), the regenerative medical
devices company, announces the launch of its new BioRinse(R)
product line for all sports medicine allografts that Tissue Regenix
distributes in the US and internationally.
The Company's BioRinse sterilisation technology platform uses
proprietary processes to produce sterile bone and soft tissue
products. The new process for sports medicine allografts causes
less damage to the tissue in order to produce an enhanced sterile
soft tissue product. The primary market for these grafts is sports
medicine, mainly consisting of tendon and ligament reconstruction
procedures in the knee, ankle, elbow, and other joints.
The Company has previously discussed plans to innovate the
processing protocols for its soft tissue products in order to
enhance performance, efficiency, and safety in the products that
Tissue Regenix already produces for the sports medicine market.
These changes will allow Tissue Regenix to capture a larger segment
of the estimated USD300 million market for allograft soft tissue
tendons for ligament reconstruction procedures of the knee.
Daniel Lee, Chief Executive Officer of Tissue Regenix,
commented: "As part of our ongoing initiatives to provide
high-quality products to our customers, we continually monitor
market dynamics and customer needs. With the launch of our new
product, we are offering an enhanced tissue allograft option. The
initial reaction of our commercial partners has been positive and
will aid our commercial efforts in both the domestic and rest of
the world markets."
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer via Walbrook PR
finnCap Ltd (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR) Tel: +44 (0)20 7933 8780
Alice Woodings/Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical device company in
regenerative medicine. The Company's patented decellularisation
technology (dCELL(R)) removes DNA and other cellular material from
animal and human soft tissue, leaving an acellular tissue scaffold
not rejected by the patient's body that can be used to repair
diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle
injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R). This biotech company specialises in regenerative
medicine and is dedicated to developing high-quality, innovative
tissue scaffolds to enhance healing opportunities in defects
created by trauma and disease. CellRight's human tissue products
may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PRLQZLFBXKLXBBB
(END) Dow Jones Newswires
September 05, 2023 02:01 ET (06:01 GMT)
Tissue Regenix (LSE:TRX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Tissue Regenix (LSE:TRX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024